On Sept. 23, 2026, the US Food and Drug Administration (FDA) approved Elevar Therapeutics’ Lyrfigtu™ (lirafugratinib) for the treatment of adult patients who have previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. Lyrfigtu is an oral, irreversible (covalent) small molecule inhibitor that selectively targets FGFR2 over FGFR1 and FGFR4. The recommended dose is 70mg taken orally once daily until disease progression or unacceptable toxicity. It is expected to be available by quarter four 2026. Cost is not yet known. Here is the prescribing information.
At a Glance
- Brand Drug: Lyrfigtu™ (lirafugratinib)
- Manufacturer: Elevar Therapeutics
- Date Approved: Sept. 23, 2026
- Indication: For the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 gene fusion or other rearrangement.
- Dosage Forms Available: 20mg and 30mg capsules
- Launch Date: Lyrfigtu is expected to be available to patients in the US by the fourth quarter of 2026.
- Estimated Annual Cost: Not yet known.
- FDA Designation: Priority Review. Breakthrough Therapy. Orphan Drug. Real-Time Oncology Review.
- CCA, also known as bile duct cancer, is rare, with about 8,000 people newly diagnosed in the US each year, according to the American Cancer Society.
- FGFR2 fusions or rearrangements occur in approximately 10% to 15% of intrahepatic CCA cases.
- Approval was based on an objective response rate (ORR) of 46% and a median duration of response of 11.8 months in 116 adult patients with FGFR2 fusion/rearrangement-positive CCA who were naïve to prior FGFR inhibitor therapy and had progressed on at least one prior regimen of chemotherapy or chemoimmunotherapy.
- The most common treatment-related side effects included mouth sores (stomatitis), a skin reaction on the hands and feet (palmar-plantar erythrodysesthesia), nail changes, alopecia and dry mouth. Other potential risks include elevated phosphate levels in the blood (hyperphosphatemia), ocular toxicity, soft tissue mineralization and embryo-fetal toxicity.
- Other FGFR inhibitors approved for FGFR2-positive CCA are Pemazyre® (pemigatinib – Incyte) and Lytgobi® (futibatinib – Taiho Oncology).
- Other pipeline agents in development for FGFR2-altered cholangiocarcinoma include InnoCare Pharma’s gunagratinib (ICP-192), an oral pan-FGFR inhibitor in phase II development, and TransThera’s tinengotinib, a multikinase inhibitor that is advancing to phase III trials.